Unigestion Holding SA Makes New Investment in Stryker Co. (NYSE:SYK)

Unigestion Holding SA purchased a new position in Stryker Co. (NYSE:SYK - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,605 shares of the medical technology company's stock, valued at approximately $580,000.

Other institutional investors also recently bought and sold shares of the company. ORG Partners LLC raised its holdings in Stryker by 788.2% in the 2nd quarter. ORG Partners LLC now owns 302 shares of the medical technology company's stock worth $102,000 after acquiring an additional 268 shares during the last quarter. Redhawk Wealth Advisors Inc. raised its stake in shares of Stryker by 9.8% in the second quarter. Redhawk Wealth Advisors Inc. now owns 615 shares of the medical technology company's stock worth $209,000 after purchasing an additional 55 shares during the last quarter. SteelPeak Wealth LLC lifted its holdings in shares of Stryker by 16.9% during the second quarter. SteelPeak Wealth LLC now owns 742 shares of the medical technology company's stock valued at $253,000 after purchasing an additional 107 shares in the last quarter. Swedbank AB boosted its position in shares of Stryker by 1.5% during the second quarter. Swedbank AB now owns 46,038 shares of the medical technology company's stock valued at $15,664,000 after buying an additional 660 shares during the last quarter. Finally, Silver Lake Advisory LLC purchased a new position in Stryker in the 2nd quarter worth about $296,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the sale, the vice president now owns 10,042 shares of the company's stock, valued at approximately $3,685,213.16. The trade was a 42.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,781 shares of company stock valued at $24,612,275. 5.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. UBS Group lifted their price target on shares of Stryker from $366.00 to $370.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 30th. Truist Financial raised their target price on shares of Stryker from $370.00 to $380.00 and gave the stock a "hold" rating in a report on Wednesday, October 30th. Evercore ISI increased their price target on Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. raised their price target on Stryker from $375.00 to $420.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 30th. Finally, Citigroup increased their target price on Stryker from $411.00 to $450.00 and gave the company a "buy" rating in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and an average target price of $404.35.

Stryker Price Performance

Shares of NYSE SYK traded down $1.15 during mid-day trading on Thursday, hitting $375.01. 846,011 shares of the company's stock traded hands, compared to its average volume of 1,260,068. The company's 50-day moving average is $372.42 and its two-hundred day moving average is $354.51. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a 1 year low of $285.79 and a 1 year high of $398.20. The company has a market capitalization of $142.96 billion, a P/E ratio of 40.23, a PEG ratio of 2.89 and a beta of 0.94.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. The business had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.46 earnings per share. On average, equities analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a $0.84 dividend. This is a positive change from Stryker's previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. Stryker's dividend payout ratio (DPR) is presently 36.01%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.